These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 26398122)

  • 41. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
    Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
    Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
    Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
    Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
    Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
    Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stromal-derived factor-1 and its receptor, CXCR4, are constitutively expressed by mouse liver sinusoidal endothelial cells: implications for the regulation of hematopoietic cell migration to the liver during extramedullary hematopoiesis.
    Mendt M; Cardier JE
    Stem Cells Dev; 2012 Aug; 21(12):2142-51. PubMed ID: 22121892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The contributory roles of the CXCL12/CXCR4/CXCR7 axis in normal and malignant hematopoiesis: A possible therapeutic target in hematologic malignancies.
    Mehrpouri M
    Eur J Pharmacol; 2022 Apr; 920():174831. PubMed ID: 35183534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dextran sulfate and stromal cell derived factor-1 promote CXCR4 expression and improve bone marrow homing efficiency of infused hematopoietic stem cells.
    Hayakawa J; Migita M; Ueda T; Fukazawa R; Adachi K; Ooue Y; Hayakawa M; Shimada T; Fukunaga Y
    J Nippon Med Sch; 2009 Aug; 76(4):198-208. PubMed ID: 19755795
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
    Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
    Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leukemia cells impair normal hematopoiesis and induce functionally loss of hematopoietic stem cells through immune cells and inflammation.
    Cui P; Zhang Y; Cui M; Li Z; Ma G; Wang R; Wang N; Huang S; Gao J
    Leuk Res; 2018 Feb; 65():49-54. PubMed ID: 29306107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia.
    Chen Y; Jacamo R; Konopleva M; Garzon R; Croce C; Andreeff M
    J Clin Invest; 2013 Jun; 123(6):2395-407. PubMed ID: 23676502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CXCR7 participates in CXCL12-mediated migration and homing of leukemic and normal hematopoietic cells.
    Melo RCC; Ferro KPV; Duarte ADSS; Olalla Saad ST
    Stem Cell Res Ther; 2018 Feb; 9(1):34. PubMed ID: 29433559
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SDF-1 and CXCR4 in normal and malignant hematopoiesis.
    Juarez J; Bendall L
    Histol Histopathol; 2004 Jan; 19(1):299-309. PubMed ID: 14702198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
    Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
    Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.
    Wuchter P; Leinweber C; Saffrich R; Hanke M; Eckstein V; Ho AD; Grunze M; Rosenhahn A
    Cell Tissue Res; 2014 Feb; 355(2):315-26. PubMed ID: 24337688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics.
    Habringer S; Lapa C; Herhaus P; Schottelius M; Istvanffy R; Steiger K; Slotta-Huspenina J; Schirbel A; Hänscheid H; Kircher S; Buck AK; Götze K; Vick B; Jeremias I; Schwaiger M; Peschel C; Oostendorp R; Wester HJ; Grigoleit GU; Keller U
    Theranostics; 2018; 8(2):369-383. PubMed ID: 29290814
    [TBL] [Abstract][Full Text] [Related]  

  • 55. ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy.
    Chen Z; Teo AE; McCarty N
    Clin Cancer Res; 2016 Jan; 22(1):187-99. PubMed ID: 26350264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1.
    Möhle R; Bautz F; Rafii S; Moore MA; Brugger W; Kanz L
    Blood; 1998 Jun; 91(12):4523-30. PubMed ID: 9616148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance.
    Hu X; Mei S; Meng W; Xue S; Jiang L; Yang Y; Hui L; Chen Y; Guan MX
    Cancer Lett; 2018 Jul; 425():1-12. PubMed ID: 29574276
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous blockade of CXCR4 results in dramatic mobilization and expansion of hematopoietic stem and progenitor cells.
    Karpova D; Ritchey JK; Holt MS; Abou-Ezzi G; Monlish D; Batoon L; Millard S; Spohn G; Wiercinska E; Chendamarai E; Yang W; Christ S; Gehrs L; Schuettpelz LG; Dembowsky K; Pettit AR; Rettig MP; Bonig H; DiPersio JF
    Blood; 2017 May; 129(21):2939-2949. PubMed ID: 28400375
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts.
    Kremer KN; Dudakovic A; Hess AD; Smith BD; Karp JE; Kaufmann SH; Westendorf JJ; van Wijnen AJ; Hedin KE
    J Biol Chem; 2015 Dec; 290(49):29478-92. PubMed ID: 26491017
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of CXCR4 in the progression and therapy of acute leukaemia.
    Su L; Hu Z; Yang YG
    Cell Prolif; 2021 Jul; 54(7):e13076. PubMed ID: 34050566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.